Sobi Valuation Multiples

Sobi Overview

About Sobi

Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

Founded

2001

HQ

Employees

1.9K

Website

sobi.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $3B

EBITDA: $1B

EV

$17B

Valuation Multiples

Multiples.vc

Start free trial

Sobi Financials

Sobi reported last 12-month revenue of $3B and EBITDA of $1B.

In the same LTM period, Sobi generated $3B in gross profit, $1B in EBITDA, and $334M in net income.

Sobi P&L

In the most recent fiscal year, Sobi reported revenue of $3B and EBITDA of $1B.

Sobi expects next 12-month revenue of XXX and NTM EBITDA of XXX

Sobi Stock Performance

Sobi has current market cap of $16B, and enterprise value of $17B.

Sobi's stock price is $45.80.

Sobi Valuation Multiples

Sobi trades at 5.3x EV/Revenue multiple, and 13.5x EV/EBITDA.

Sobi Financial Valuation Multiples

As of April 19, 2026, Sobi has market cap of $16B and EV of $17B.

Equity research analysts estimate Sobi's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Sobi has a P/E ratio of 47.4x.

Sobi Margins & Growth Rates

Sobi's revenue in the last 12 month grew by 12%.

Sobi's revenue per employee in the last FY averaged $1.6M, while opex per employee averaged $1.2M for the same period.

Sobi's rule of 40 is 50% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Sobi's rule of X is 69% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Sobi Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Sobi M&A Activity

Sobi acquired XXX companies to date.

Last acquisition by Sobi was on XXXXXXXX, XXXXX. Sobi acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Sobi Investment Activity

Sobi invested in XXX companies to date.

Sobi made its latest investment on XXXXXXXX, XXXXX. Sobi invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).